{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:09:37Z","timestamp":1792782577418,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Southern California","id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The addition of venetoclax to hypomethylating agents (HMAs) is standard for older adults with newly diagnosed acute myeloid leukemia (AML). However, prolonged venetoclax (VEN) exposure can cause cytopenias and infections, raising questions about optimal duration. We conducted a single\u2011center retrospective study of 102 patients treated between 2018 and 2025 with azacitidine or decitabine plus VEN administered for 14 (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200922), 21 (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200948), or 28 (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200932) days per 28\u2011day cycle. Baseline cytogenetic and molecular profiling, responses by 2022\/2024 ELN criteria, measurable residual disease (MRD), cumulative incidence of relapse (CIR), disease\u2011free survival (DFS), and overall survival (OS) were analyzed using competing\u2011risks regression and Cox models. Median age was 68 years and patients received a median of 4 cycles. Composite remission (CR\/CRi\/CRh\/MLFS) was 66.7%, with MRD negativity in 75.0% of responders. Remission and MRD negativity rates did not differ significantly across VEN\u2011duration cohorts. Median OS and DFS were 17.3 and 12.3 months, respectively, with no significant differences in OS, DFS, and CIR between 14\u2011, 21\u2011, and 28\u2011day cohorts. Grade\u2009\u2265\u20093 cytopenias and transfusion independence rates also did not differ significantly. In this cohort, shortening VEN exposure to 14 or 21 days did not show a significant difference in response, survival, relapse risk, and toxicity profiles relative to a 28\u2011day schedule in our cohort. These findings support further prospective evaluation of reduced VEN durations in this population.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-07219-2","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:04:56Z","timestamp":1785819896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival"],"prefix":"10.1007","volume":"105","author":[{"given":"Anush A.","family":"Ginosyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karam","family":"Ashouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir","family":"Baya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Humayun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ireland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karrune","family":"Woan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Leon","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Yaghmour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"issue":"3","key":"7219_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >\u200930% blasts. Blood 126(3):291\u2013299","journal-title":"Blood"},{"issue":"7","key":"7219_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"issue":"2","key":"7219_CR3","doi-asserted-by":"publisher","first-page":"E63","DOI":"10.1002\/ajh.27180","volume":"99","author":"O Karrar","year":"2024","unstructured":"Karrar O, Abdelmagid M, Rana M, Iftikhar M, McCullough K, Al-Kali A et al (2024) Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. Am J Hematol 99(2):E63\u2013E6","journal-title":"Am J Hematol"},{"issue":"4","key":"7219_CR4","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bcp.13175","volume":"83","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M et al (2017) Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin Pharmacol 83(4):846\u2013854","journal-title":"Br J Clin Pharmacol"},{"key":"7219_CR5","volume-title":"Venclexta (venetoclax) tablets, for oral use [package insert]","author":"A Inc","year":"2026","unstructured":"Inc A (2026) Venclexta (venetoclax) tablets, for oral use [package insert]. AbbVie Inc., North Chicago, IL"},{"issue":"12","key":"7219_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"issue":"21","key":"7219_CR7","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL et al (2024) Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood 144(21):2169\u20132173","journal-title":"Blood"},{"issue":"26","key":"7219_CR8","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL et al (2021) 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138(26):2753\u20132767","journal-title":"Blood"},{"issue":"1","key":"7219_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41408-025-01324-7","volume":"15","author":"M Kanaya","year":"2025","unstructured":"Kanaya M, Onozawa M, Matsukawa T, Miyashita N, Fujii F, Yoshida S et al (2025) Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net. Blood Cancer J 15(1):118","journal-title":"Blood Cancer J"},{"issue":"22","key":"7219_CR10","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1182\/blood.2024025834","volume":"144","author":"M Goldfinger","year":"2024","unstructured":"Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica RA et al (2024) A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort. Blood 144(22):2360\u20132363","journal-title":"Blood"},{"issue":"1","key":"7219_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41408-025-01269-x","volume":"15","author":"C Willekens","year":"2025","unstructured":"Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N et al (2025) Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. Blood Cancer J 15(1):68","journal-title":"Blood Cancer J"},{"issue":"3","key":"7219_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","volume":"102","author":"M Aiba","year":"2023","unstructured":"Aiba M, Shigematsu A, Suzuki T, Miyagishima T (2023) Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia. Ann Hematol 102(3):541\u2013546","journal-title":"Ann Hematol"},{"issue":"Supplement 1","key":"7219_CR13","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/blood-2025-3398","volume":"146","author":"G Aspas Requena","year":"2025","unstructured":"Aspas Requena G, Chorao P, Chraibi S, Tauveron-Jalenques U, Belhabri A, Tavernier E et al (2025) Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study. Blood 146(Supplement 1):3398","journal-title":"Blood"},{"issue":"4","key":"7219_CR14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","volume":"8","author":"A Bataller","year":"2024","unstructured":"Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG et al (2024) Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927\u2013935","journal-title":"Blood Adv"},{"key":"7219_CR15","unstructured":"Borate U, Huang Y, Lin TL, Handa S, Swords R, Lachowiez C, Traer E, Stock W, Odenike O, Patel A, Baer M, Duong V, Stein E, Blum W, Vale C, Curran E, Madanat YF, Olin R, Schiller G, Nichols A, Williams L, Heerema N, Johnson M, Chen T, Marcus S, Martycz M, Stefanos M, Rosenberg L, DeGennaro L, Gruenbaum L, Burd A, Byrd J, Druker B, Levine R, Yocum A, Mims A, Zeidner J (2026) OPTI-AML: prospective randomized phase 2 trial of 28 versus 14\u00a0day schedule of venetoclax and azacitidine for 2 cycles in newly diagnosed genomically agnostic acute myeloid leukemia patients\u2009\u2265\u200960 years. European Hematol Assoc Lib"},{"issue":"18","key":"7219_CR16","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1182\/bloodadvances.2023010312","volume":"7","author":"A Stengel","year":"2023","unstructured":"Stengel A, Meggendorfer M, Walter W, Baer C, Nadarajah N, Hutter S et al (2023) Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS. Blood Adv 7(18):5540\u20135548","journal-title":"Blood Adv"},{"issue":"8","key":"7219_CR17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1200\/JCO.21.01546","volume":"40","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ et al (2022) Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol 40(8):855\u2013865","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07219-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07219-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07219-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:50:39Z","timestamp":1791669039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07219-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":17,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["7219"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07219-2","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"4 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was conducted in accordance with the ethical standards of the Declaration of Helsinki. The study protocol was reviewed and approved by the University of Southern California Institutional Review Board. As this study involves retrospective data analysis, the requirement for informed consent was waived by the committee. All data were anonymized prior to analysis to ensure the privacy and confidentiality of the participants.","order":1,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AA served on the speaker bureau for Johnson & Johnson. IS served on the advisory board for Recordati Rare Diseases. GY served on the advisory board for Abbvie, Daiichi, and Astazeneca; served on the speaker bureau for GSK, Rigel, Servier, Jazz, Bristol Myers Squibb, Kite, SOBI, Incyte, Secura Bio, Astellas, Blueprint, and Stemline therapeutics.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"415"}}